---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-24-000053"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:15:06.804179+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Q3 net loss $1.14/shr; cash $458M; Phase 2b data catalysts ahead

## Summary
- Net loss $32.9M ($1.14/shr) vs $37.3M ($1.41/shr) year-ago; nine-month loss $4.46/shr.
- Collaboration revenue $30M in Q3 vs $3.3M year-ago due to Jemperli milestone and royalties.
- Cash and investments $458M; reaffirms cash runway through year-end 2026.
- Top-line Phase 2b data for ANB032 in atopic dermatitis expected December 2024.
- Top-line Phase 2b data for rosnilimab in RA expected February 2025.

## SEC filing metadata
- accession: 0001370053-24-000053
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000053/0001370053-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000053/anab-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-24-000053
- JSON: https://secwatch.observer/filing/0001370053-24-000053.json
- Plain text: https://secwatch.observer/filing/0001370053-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.